Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301599914> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4301599914 endingPage "1488" @default.
- W4301599914 startingPage "1481" @default.
- W4301599914 abstract "Increasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranasal formulation of the water-soluble, small-molecule, nicotinic acetylcholine receptor (nAChR) agonist varenicline (Tyrvaya™) has been approved in the USA for the treatment of DED. Twice-daily administration of varenicline solution nasal spray resulted in rapid, statistically significant and clinically meaningful improvements in the signs and symptoms of DED over a period of 4 weeks in two pivotal studies (ONSET-1 and -2). The efficacy of varenicline solution was maintained over a longer-term period of 12 weeks in a third study (MYSTIC). Consistent with the nasal route of delivery, the most common adverse events reported by varenicline solution recipients were non-ocular in nature (mild and transient sneezing and cough). Thus, varenicline solution nasal spray is a rapidly-acting, effective and generally well tolerated treatment for DED that offers several potentially useful advantages over existing topical ocular therapies in terms of increasing endogenous tear secretion and reducing ophthalmic treatment burden. Dry eye disease (DED) is a common, often chronic, condition characterized by symptoms, such as irritation and blurred vision, that can negatively impact on quality of life. DED occurs due to the production of insufficient or unstable tear films and is typically treated with topically applied artificial tears and medications that reduce accompanying inflammation of the ocular surface. Using an intranasal formulation of the nicotinic acetylcholine receptor (nAChR) agonist varenicline (Tyrvaya™) to enhance natural tear production represents a novel approach to DED treatment. Varenicline solution nasal spray led to fast and sustained improvements in the signs and symptoms of DED in clinical trials of up to 12 weeks’ duration. Varenicline solution was also generally well tolerated, with the most common adverse events being mild and transient sneezing and cough. Varenicline solution nasal spray is a new type of treatment for DED that may increase natural tear production, have better ocular tolerability and, for some patients, be easier and/or more convenient to use compared with traditional topical therapies." @default.
- W4301599914 created "2022-10-05" @default.
- W4301599914 creator A5069047133 @default.
- W4301599914 date "2022-09-01" @default.
- W4301599914 modified "2023-10-09" @default.
- W4301599914 title "Varenicline Solution Nasal Spray: A Review in Dry Eye Disease" @default.
- W4301599914 cites W2001968948 @default.
- W4301599914 cites W2027975733 @default.
- W4301599914 cites W2037972678 @default.
- W4301599914 cites W2070026700 @default.
- W4301599914 cites W2090305797 @default.
- W4301599914 cites W2141246891 @default.
- W4301599914 cites W2144919760 @default.
- W4301599914 cites W2346421161 @default.
- W4301599914 cites W2735923669 @default.
- W4301599914 cites W2737439597 @default.
- W4301599914 cites W2737787547 @default.
- W4301599914 cites W2739410682 @default.
- W4301599914 cites W2890648071 @default.
- W4301599914 cites W2895808676 @default.
- W4301599914 cites W2900424219 @default.
- W4301599914 cites W2965678854 @default.
- W4301599914 cites W3000127325 @default.
- W4301599914 cites W3036870694 @default.
- W4301599914 cites W3128891592 @default.
- W4301599914 cites W3138260129 @default.
- W4301599914 cites W3142116570 @default.
- W4301599914 cites W3196925025 @default.
- W4301599914 cites W3207648359 @default.
- W4301599914 cites W3212838083 @default.
- W4301599914 cites W4200345915 @default.
- W4301599914 cites W4200467235 @default.
- W4301599914 cites W4229453175 @default.
- W4301599914 cites W4281648674 @default.
- W4301599914 cites W4282933638 @default.
- W4301599914 cites W4282940162 @default.
- W4301599914 cites W4299394916 @default.
- W4301599914 doi "https://doi.org/10.1007/s40265-022-01782-4" @default.
- W4301599914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36197638" @default.
- W4301599914 hasPublicationYear "2022" @default.
- W4301599914 type Work @default.
- W4301599914 citedByCount "6" @default.
- W4301599914 countsByYear W43015999142022 @default.
- W4301599914 countsByYear W43015999142023 @default.
- W4301599914 crossrefType "journal-article" @default.
- W4301599914 hasAuthorship W4301599914A5069047133 @default.
- W4301599914 hasBestOaLocation W43015999141 @default.
- W4301599914 hasConcept C118487528 @default.
- W4301599914 hasConcept C142724271 @default.
- W4301599914 hasConcept C2777053506 @default.
- W4301599914 hasConcept C2777843972 @default.
- W4301599914 hasConcept C2779159986 @default.
- W4301599914 hasConcept C2780973058 @default.
- W4301599914 hasConcept C42219234 @default.
- W4301599914 hasConcept C71924100 @default.
- W4301599914 hasConcept C85663871 @default.
- W4301599914 hasConcept C98274493 @default.
- W4301599914 hasConceptScore W4301599914C118487528 @default.
- W4301599914 hasConceptScore W4301599914C142724271 @default.
- W4301599914 hasConceptScore W4301599914C2777053506 @default.
- W4301599914 hasConceptScore W4301599914C2777843972 @default.
- W4301599914 hasConceptScore W4301599914C2779159986 @default.
- W4301599914 hasConceptScore W4301599914C2780973058 @default.
- W4301599914 hasConceptScore W4301599914C42219234 @default.
- W4301599914 hasConceptScore W4301599914C71924100 @default.
- W4301599914 hasConceptScore W4301599914C85663871 @default.
- W4301599914 hasConceptScore W4301599914C98274493 @default.
- W4301599914 hasIssue "14" @default.
- W4301599914 hasLocation W43015999141 @default.
- W4301599914 hasLocation W43015999142 @default.
- W4301599914 hasLocation W43015999143 @default.
- W4301599914 hasOpenAccess W4301599914 @default.
- W4301599914 hasPrimaryLocation W43015999141 @default.
- W4301599914 hasRelatedWork W187285789 @default.
- W4301599914 hasRelatedWork W2067721561 @default.
- W4301599914 hasRelatedWork W2126385856 @default.
- W4301599914 hasRelatedWork W2160013260 @default.
- W4301599914 hasRelatedWork W2290109400 @default.
- W4301599914 hasRelatedWork W2416347556 @default.
- W4301599914 hasRelatedWork W3045325031 @default.
- W4301599914 hasRelatedWork W4284703589 @default.
- W4301599914 hasRelatedWork W4301599914 @default.
- W4301599914 hasRelatedWork W3093522670 @default.
- W4301599914 hasVolume "82" @default.
- W4301599914 isParatext "false" @default.
- W4301599914 isRetracted "false" @default.
- W4301599914 workType "article" @default.